These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 22551030

  • 21. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z.
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [Abstract] [Full Text] [Related]

  • 22. Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling.
    Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL.
    Risk Anal; 2006 Dec; 26(6):1571-80. PubMed ID: 17184398
    [Abstract] [Full Text] [Related]

  • 23. [Possible method of eradication of poliomyelitis as an infection].
    Seĭbil' VB, Malyshkina LP.
    Zh Mikrobiol Epidemiol Immunobiol; 2012 Dec; (3):107-13. PubMed ID: 22830285
    [Abstract] [Full Text] [Related]

  • 24. Progress toward global eradication of poliomyelitis, 2001.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2002 Mar 29; 51(12):253-6. PubMed ID: 11939704
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
    Samoilovich EO, Feldman EV, Yermalovich MA, Protas II, Titov LP.
    Cent Eur J Public Health; 2003 Dec 29; 11(4):213-8. PubMed ID: 14768785
    [Abstract] [Full Text] [Related]

  • 27. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
    Duintjer Tebbens RJ, Thompson KM.
    Expert Rev Vaccines; 2018 Aug 29; 17(8):739-751. PubMed ID: 30056767
    [Abstract] [Full Text] [Related]

  • 28. Circulating vaccine derived polio viruses and their impact on global polio eradication.
    Wagner BG, Earn DJ.
    Bull Math Biol; 2008 Jan 29; 70(1):253-80. PubMed ID: 17934778
    [Abstract] [Full Text] [Related]

  • 29. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.
    Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM.
    Risk Anal; 2006 Dec 29; 26(6):1471-505. PubMed ID: 17184393
    [Abstract] [Full Text] [Related]

  • 30. Cost analysis of post-polio certification immunization policies.
    Sangrujee N, Cáceres VM, Cochi SL.
    Bull World Health Organ; 2004 Jan 29; 82(1):9-15. PubMed ID: 15106295
    [Abstract] [Full Text] [Related]

  • 31. [Worldwide eradication of poliomyelitis].
    Rasch G, Schreier E, Kiehl W, Kurth R.
    Wien Klin Wochenschr; 2001 Oct 30; 113(20-21):839-45. PubMed ID: 11732120
    [Abstract] [Full Text] [Related]

  • 32. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.
    Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y.
    Vaccine; 2015 Mar 03; 33(10):1235-42. PubMed ID: 25600519
    [Abstract] [Full Text] [Related]

  • 33. Polio control after certification: major issues outstanding.
    Fine PE, Oblapenko G, Sutter RW.
    Bull World Health Organ; 2004 Jan 03; 82(1):47-52. PubMed ID: 15106300
    [Abstract] [Full Text] [Related]

  • 34. The polio endgame.
    Minor P.
    Hum Vaccin Immunother; 2014 Jan 03; 10(7):2106-8. PubMed ID: 25608050
    [Abstract] [Full Text] [Related]

  • 35. [Vaccination strategies for the global eradication of poliomyelitis].
    Bompart F.
    Bull Soc Pathol Exot; 2004 Nov 03; 97(4):288-92. PubMed ID: 17304754
    [Abstract] [Full Text] [Related]

  • 36. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
    Kalkowska DA, Thompson KM.
    Risk Anal; 2021 Feb 03; 41(2):312-319. PubMed ID: 32936466
    [Abstract] [Full Text] [Related]

  • 37. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.
    Cáceres VM, Sutter RW.
    Clin Infect Dis; 2001 Aug 15; 33(4):531-41. PubMed ID: 11462191
    [Abstract] [Full Text] [Related]

  • 38. Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2009 Sep 18; 58(36):1002-6. PubMed ID: 19763076
    [Abstract] [Full Text] [Related]

  • 39. [The role of Sabin inactivated poliovirus vaccine in the final phase of global polio eradication].
    Dong SZ, Zhu WB.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec 06; 50(12):1032-1035. PubMed ID: 28057104
    [Abstract] [Full Text] [Related]

  • 40. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
    Băicuş A, Persu A, Combiescu M, Aubert-Combiescu A.
    Roum Arch Microbiol Immunol; 2007 Dec 06; 66(1-2):44-50. PubMed ID: 18928063
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.